CN109289090A - 一种胰岛移植微环境及其构建方法 - Google Patents
一种胰岛移植微环境及其构建方法 Download PDFInfo
- Publication number
- CN109289090A CN109289090A CN201811282813.9A CN201811282813A CN109289090A CN 109289090 A CN109289090 A CN 109289090A CN 201811282813 A CN201811282813 A CN 201811282813A CN 109289090 A CN109289090 A CN 109289090A
- Authority
- CN
- China
- Prior art keywords
- bracket
- microenvironment
- pancreatic islets
- transplantation
- islets transplantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002054 transplantation Methods 0.000 title claims abstract description 40
- 210000004153 islets of langerhan Anatomy 0.000 title claims abstract description 35
- 238000010276 construction Methods 0.000 title abstract description 4
- 210000000496 pancreas Anatomy 0.000 claims abstract description 32
- 239000013078 crystal Substances 0.000 claims abstract description 17
- 210000000130 stem cell Anatomy 0.000 claims abstract description 17
- 108010073385 Fibrin Proteins 0.000 claims abstract description 11
- 102000009123 Fibrin Human genes 0.000 claims abstract description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229950003499 fibrin Drugs 0.000 claims abstract description 11
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
- 229920005573 silicon-containing polymer Polymers 0.000 claims abstract description 9
- 230000001681 protective effect Effects 0.000 claims abstract description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 5
- 239000002210 silicon-based material Substances 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 4
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 210000005059 placental tissue Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000003954 umbilical cord Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 5
- 230000033115 angiogenesis Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000006058 immune tolerance Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/20—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种胰岛移植微环境及其构建方法,该方法通过应用医用有机硅材料聚二甲基硅氧烷和可溶性晶体构建三维支架,为胰岛提供机械稳定的空间;同时支架内预先种植间充质干细胞,可调节移植胰岛免疫耐受和促进支架内移植胰岛血管生成的作用;支架外应用胞外基质纤维蛋白和凝血酶制成的生物胶保护膜,为移植胰岛提供一个可隔绝血液细胞的直接接触和免疫系统的攻击的微环境。本发明可为移植胰岛提供一个有效的微环境,保护移植胰岛的功能。
Description
技术领域
本发明属于生物技术领域,具体涉及一种胰岛移植微环境及其构建方法,为移植胰岛提供生存的微环境。
背景技术
胰岛移植是一种治疗糖尿病的有效方法,通过胰岛移植可以实现血糖的生理正常,避免严重低血糖发生,提高C肽水平,甚至摆脱胰岛素治疗。目前胰岛移植主要采用门静脉肝内移植的方式。然而多达60%的胰岛在移植过程损害或失功,严重影响胰岛移植的治疗效果。研究证明造成大量胰岛失功的主要原因有:1)胰岛在肝内与血液直接接触,引起即刻血液介导的炎症反应(IBMIR),是移植后瞬间胰岛失功的主要原因。2)移植后胰岛无血管期的低氧状态引起胰岛细胞凋亡,同时肝内低氧环境激发自然免疫系统,释放炎症因子如IFNγ,TNF-α,IL-1B 继而损伤胰岛。3)肝脏微环境中高浓度的免疫抑制剂药物和胃肠毒物损害胰岛功能和影响胰岛血管生成。4)肝内含有丰富的NKT细胞,活化的NKT细胞产生大量的细胞因子,如IL-4,IL-10,IFN-γ和TNFβ激活CD4 Th1细胞,CD8细胞毒性T细胞以及自然免疫系统的细胞,这些免疫反应可能导致胰岛的损伤,同时促进免疫的识别和移植胰岛的排斥。因此,以肝脏作为胰岛移植位点具有明显的缺陷,肝脏微环境并不适于胰岛移植。
理想的胰岛移植微环境需要满足以下条件:1)丰富的血供,足够的移植空间;2)最小的刺激免疫系统;3)快速血管化,足够的养分供应;4)模拟生理的血糖感应和促进胰岛素的分泌。5)容易随访监测。一个位点具有这些特征才能为移植的胰岛提供存活的环境并保证其功能。为此研究者进行了许多尝试,如胰腺,胃粘膜下层,横纹肌,腹膜,大网膜,骨髓,肾包膜,淋巴结,脾以及一些免疫豁免的位点如眼仓,睾丸,胸腺等,但是人体内还没有一个理想的位点能同时满足以上所有的要求。
发明内容
本发明的目的在于通过生物工程方式,用干细胞、胞外基质和生物支架共同构建一个“人工胰腺”,为胰岛移植提供良好的微环境,减少以上因素的影响对胰岛功能的影响,提高胰岛移植治疗糖尿病的效果。
为实现上述目的,本发明采用如下技术方案:
一种胰岛移植微环境,由医用有机硅材料和晶体构建三维支架;支架内种植间充质干细胞,支架外是生物胶形成保护膜。
所述有机硅材料是商品化的聚二甲基硅氧烷。
所述的晶体为NaCl晶体或其它可溶性晶体,颗粒大小为100~400 μm。
所述的聚二甲基硅氧烷与晶体比例为质量比1:10~4:1。
所述的间充质干细胞的来源为脐带、骨髓、脂肪、胎盘组织中的一种。
所述的生物胶保护膜是由自体血浆中的纤维蛋白与凝血酶形成的。
所述的凝血酶浓度为100~2000 IU/ml。
所述的自体血浆与凝血酶的比例为体积比10:1~1:1。
一种胰岛移植微环境的制备方法,包括以下步骤:
(1)取NaCl晶体,60℃烤箱干燥24~48小时;
(2)取商品化的聚二甲基硅氧烷与NaCl晶体按比例混合均匀;
(3)将步骤(2)得到的产物倒入模具中;
(4)正向压力1000 PSI压缩,固化4-12小时;
(5)将形成的支架从模具中取出,放入去离子蒸馏水中淘洗2天,将NaCl完全淘洗除去;
(6)将支架放入2M NaOH中50℃孵育24-48小时;
(7)将步骤(6)孵育后的支架用蒸馏水清洗三次;
(8)60℃烤箱干燥4小时,将支架烘干后,高压灭菌;
(9)用含有体积分数10%自体血清的PBS缓冲液浸泡支架过夜;
(10)将支架放入培养皿中,加入1~5×106/ml的间充质干细胞的细胞悬液培养过夜;
(11)取出含间充质干细胞的支架,放入新的培养皿中;
(12)将分离的胰岛浓缩于50~1000μl的1640培养基中;
(13)将步骤(12)得到的胰岛滴加在步骤(11)获得的支架上,利用重力作用,装载入支架巨孔中;
(14)取自体血浆,加入凝血酶,混合均匀后,迅速滴加于支架外围,形成一层包绕支架的纤维蛋白胶,即制备得到含有间充质干细胞、胰岛细胞、胞外基质保护膜组成的移植胰岛微环境。
根据需要将制备得到的胰岛移植微环境应用于构建胰岛移植环境中。
本发明的优点在于:
(1)本发明可以为胰岛提供稳定的物理空间环境;本发明采用的有机硅材料为医用的聚二甲基硅氧烷,具有良好的生物稳定性和生物相容性,无毒无味,具有良好的生理惰性、化学稳定性、弹性、透气性,易于加工等优点,广泛的应用于药品、化妆品、食品、建筑等各领域。
(2)本发明可以物理隔离胰岛与血液炎症细胞、免疫细胞的直接接触,降低移植胰岛的排斥反应和炎症反应,促进胰岛的存活。
(3)本发明含有间充质干细胞可以促进移植胰岛血管生成和抑制炎症、免疫反应,促进胰岛存活。
附图说明
图1为胰岛支架。
图2为装载间充质干细胞(黑色箭头所示)和胰岛细胞(白色箭头所示)的支架。
图3为胰岛移植微环境对糖尿病大鼠血糖的影响。
图4为支架内可见间充质干细胞(黑色箭头所示)和胰岛(白色箭头所示)。
图5为支架内胰岛(白色箭头所示)可见血管生成(黑色箭头所示)。
图6为支架内胰岛经胰岛素组化染色阳性(箭头所示)。
具体实施方式
实施例1
(1)取颗粒大小为100~400 μm的NaCl晶体,60℃烤箱干燥24~48小时。
(2)取商品化的聚二甲基硅氧烷与NaCl晶体按质量比1:10混合均匀。
(3)将步骤(2)得到的产物倒入模具中。
(4)正向压力1000 PSI压缩,固化4小时。
(5)将形成的支架从模具中取出,放入去离子蒸馏水中淘洗2天,将NaCl完全淘洗除去。
(6)将支架放入2M NaOH中50℃孵育24小时。
(7)将步骤(6)孵育后的支架用蒸馏水清洗三次。
(8)60℃烤箱干燥4小时,将支架烘干后,高压灭菌。
(9)用含有体积分数10%自体血清的PBS缓冲液浸泡支架过夜。
(10)将支架放入培养皿中,加入骨髓间充质干细胞的细胞悬液(2×106/ml)培养过夜。
(11)取出含间充质干细胞的支架,放入新的培养皿中。
(12)将分离的SD大鼠胰岛浓缩于50 μl的1640培养基中。
(13)将步骤(12)得到的胰岛滴加在步骤(11)获得的支架上,利用重力作用,装载入支架巨孔中。
(14)取SD大鼠血浆,按体积比10:1加入凝血酶,凝血酶浓度为2000 IU/ml,混合均匀后,迅速滴加于支架外围,形成一层包绕支架的纤维蛋白胶,即制备得到含有间充质干细胞、胰岛细胞、胞外基质保护膜组成的移植胰岛微环境。
实施例1构建得到的移植胰岛微环境见图2,装载间充质干细胞为黑色箭头所示,胰岛细胞为白色箭头所示。
将构建的胰岛支架微环境移植到糖尿病大鼠中,观察糖尿病大鼠的血糖水平。结果显示,该方法构建的胰岛支架可明显降低糖尿病大鼠血糖(见图3),病理结果HE染色显示,支架内存在胰岛(白色箭头所示)和间充质干细胞(黑色箭头所示)(见图4),胰岛内有明显的血管生成(见图5,胰岛白色箭头所示,生成血管黑色箭头所示);且经胰岛素特异性免疫组化染色显示,移植的胰岛显示胰岛素阳性(见图6,箭头所示),显示胰岛具有良好的功能活性。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (10)
1.一种胰岛移植微环境,其特征在于由医用有机硅材料和晶体构建三维支架;支架内种植间充质干细胞,支架外是生物胶形成保护膜。
2.根据权利要求1所述的一种胰岛移植微环境,其特征在于,所述有机硅材料是商品化的聚二甲基硅氧烷。
3.根据权利要求1所述的一种胰岛移植微环境,其特征在于,所述的晶体为NaCl晶体或其它可溶性晶体,颗粒大小为100~400 μm。
4.根据权利要求1所述的一种胰岛移植微环境,其特征在于,所述的聚二甲基硅氧烷与晶体比例为质量比1:10~4:1。
5.根据权利要求1所述的一种胰岛移植微环境,其特征在于,所述的间充质干细胞的来源为脐带、骨髓、脂肪、胎盘组织中的一种。
6.根据权利要求1所述的一种胰岛移植微环境,其特征在于,所述的生物胶保护膜是由自体血浆中的纤维蛋白与凝血酶形成的。
7.根据权利要求6所述的一种胰岛移植微环境,其特征在于,所述的凝血酶浓度为100~2000 IU/ml。
8.根据权利要求6所述的一种胰岛移植微环境,其特征在于,所述的自体血浆与凝血酶的比例为体积比10:1~1:1。
9.如权利要求1所述的一种胰岛移植微环境的制备方法,其特征在于,包括以下步骤:
(1)取NaCl晶体,60℃烤箱干燥24~48小时;
(2)取商品化的聚二甲基硅氧烷与NaCl晶体按比例混合均匀;
(3)将步骤(2)得到的产物倒入模具中;
(4)正向压力1000 PSI压缩,固化4-12小时;
(5)将形成的支架从模具中取出,放入去离子蒸馏水中淘洗2天,将NaCl完全淘洗除去;
(6)将支架放入2M NaOH中50℃孵育24-48小时;
(7)将步骤(6)孵育后的支架用蒸馏水清洗三次;
(8)60℃烤箱干燥4小时,将支架烘干后,高压灭菌;
(9)用含有体积分数10%自体血清的PBS缓冲液浸泡支架过夜;
(10)将支架放入培养皿中,加入1~5×106/ml的间充质干细胞的细胞悬液培养过夜;
(11)取出含间充质干细胞的支架,放入新的培养皿中;
(12)将分离的胰岛浓缩于50 μl~1000 μl的1640培养基中;
(13)将步骤(12)得到的胰岛滴加在步骤(11)获得的支架上,利用重力作用,装载入支架巨孔中;
(14)取自体血浆,加入凝血酶,混合均匀后,迅速滴加于支架外围,形成一层包绕支架的纤维蛋白胶,即制备得到含有间充质干细胞、胰岛细胞、胞外基质保护膜组成的移植胰岛微环境。
10.如权利要求1-9任一所述一种胰岛移植微环境在构建胰岛移植环境中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811282813.9A CN109289090A (zh) | 2018-10-31 | 2018-10-31 | 一种胰岛移植微环境及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811282813.9A CN109289090A (zh) | 2018-10-31 | 2018-10-31 | 一种胰岛移植微环境及其构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109289090A true CN109289090A (zh) | 2019-02-01 |
Family
ID=65145107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811282813.9A Pending CN109289090A (zh) | 2018-10-31 | 2018-10-31 | 一种胰岛移植微环境及其构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109289090A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109847102A (zh) * | 2019-02-28 | 2019-06-07 | 山西宾大干细胞生物科技有限公司 | 一种间充质干细胞人工胰岛的制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528166A (zh) * | 2006-08-29 | 2009-09-09 | 阿克伦大学 | 用于产生胰岛素的可植入装置 |
CN101686854A (zh) * | 2007-03-09 | 2010-03-31 | 阿克伦大学 | 生物人工胰及其制备方法 |
CN101716382A (zh) * | 2009-12-02 | 2010-06-02 | 浙江大学 | 一种质粒dna/纤维蛋白凝胶/聚合物三元复合支架的制备方法 |
US20140050766A1 (en) * | 2011-02-14 | 2014-02-20 | Technion Research And Development Foundation Ltd. | Tissue engineering construct comprising fibrin |
CN104245002A (zh) * | 2012-02-01 | 2014-12-24 | 生物资源资本公司 | 用于细胞移殖的基体 |
CN105349517A (zh) * | 2008-11-14 | 2016-02-24 | 维赛特公司 | 源于人多能干细胞的胰腺细胞的包封 |
CN106047791A (zh) * | 2015-04-16 | 2016-10-26 | 国立大学法人京都大学 | 模拟胰岛的制造方法 |
WO2018092962A1 (ko) * | 2016-11-15 | 2018-05-24 | 서울대학교 산학협력단 | 산소 발생 스캐폴드 및 이의 제조방법 |
US20180185550A1 (en) * | 2017-01-05 | 2018-07-05 | The Regents Of The University Of Michigan | Microporous Hydrogel Scaffolds for Cell Transplantation |
-
2018
- 2018-10-31 CN CN201811282813.9A patent/CN109289090A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528166A (zh) * | 2006-08-29 | 2009-09-09 | 阿克伦大学 | 用于产生胰岛素的可植入装置 |
CN101686854A (zh) * | 2007-03-09 | 2010-03-31 | 阿克伦大学 | 生物人工胰及其制备方法 |
CN105349517A (zh) * | 2008-11-14 | 2016-02-24 | 维赛特公司 | 源于人多能干细胞的胰腺细胞的包封 |
CN101716382A (zh) * | 2009-12-02 | 2010-06-02 | 浙江大学 | 一种质粒dna/纤维蛋白凝胶/聚合物三元复合支架的制备方法 |
US20140050766A1 (en) * | 2011-02-14 | 2014-02-20 | Technion Research And Development Foundation Ltd. | Tissue engineering construct comprising fibrin |
CN104245002A (zh) * | 2012-02-01 | 2014-12-24 | 生物资源资本公司 | 用于细胞移殖的基体 |
CN106047791A (zh) * | 2015-04-16 | 2016-10-26 | 国立大学法人京都大学 | 模拟胰岛的制造方法 |
WO2018092962A1 (ko) * | 2016-11-15 | 2018-05-24 | 서울대학교 산학협력단 | 산소 발생 스캐폴드 및 이의 제조방법 |
US20180185550A1 (en) * | 2017-01-05 | 2018-07-05 | The Regents Of The University Of Michigan | Microporous Hydrogel Scaffolds for Cell Transplantation |
Non-Patent Citations (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109847102A (zh) * | 2019-02-28 | 2019-06-07 | 山西宾大干细胞生物科技有限公司 | 一种间充质干细胞人工胰岛的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shiekh et al. | Oxygen-releasing antioxidant cryogel scaffolds with sustained oxygen delivery for tissue engineering applications | |
Chaimov et al. | Innovative encapsulation platform based on pancreatic extracellular matrix achieve substantial insulin delivery | |
Guruswamy Damodaran et al. | Decellularized pancreas as a native extracellular matrix scaffold for pancreatic islet seeding and culture | |
Ludwig et al. | A novel device for islet transplantation providing immune protection and oxygen supply | |
Marchioli et al. | Fabrication of three-dimensional bioplotted hydrogel scaffolds for islets of Langerhans transplantation | |
Lee et al. | In situ formation and collagen-alginate composite encapsulation of pancreatic islet spheroids | |
Enck et al. | Effect of alginate matrix engineered to mimic the pancreatic microenvironment on encapsulated islet function | |
Dufrane et al. | Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression | |
Sakai et al. | Development of mammalian cell-enclosing subsieve-size agarose capsules (< 100 μm) for cell therapy | |
Bloch et al. | Functional activity of insulinoma cells (INS‐1E) and pancreatic islets cultured in agarose cryogel sponges | |
Liao et al. | Maintaining functional islets through encapsulation in an injectable saccharide–peptide hydrogel | |
Evron et al. | Oxygen supply by photosynthesis to an implantable islet cell device | |
Gryshkov et al. | Multipotent stromal cells derived from common marmoset Callithrix jacchus within alginate 3D environment: effect of cryopreservation procedures | |
Del Guerra et al. | Entrapment of dispersed pancreatic islet cells in CultiSpher‐S macroporous gelatin microcarriers: Preparation, in vitro characterization, and microencapsulation | |
Yu et al. | Enhancement of subcutaneously transplanted β cell survival using 3D stem cell spheroids with proangiogenic and prosurvival potential | |
Kepsutlu et al. | Design of bioartificial pancreas with functional micro/nano-based encapsulation of islets | |
Tse et al. | Minireview: directed differentiation and encapsulation of islet β-cells—recent advances and future considerations | |
CN109289090A (zh) | 一种胰岛移植微环境及其构建方法 | |
Inoo et al. | Insulin secretion of mixed insulinoma aggregates-gelatin hydrogel microspheres after subcutaneous transplantation | |
CN109957539A (zh) | 一种人造胰岛组织及其制备和应用 | |
Li et al. | Engineering a functional thyroid as a potential therapeutic substitute for hypothyroidism treatment: a systematic review | |
Kaneko et al. | Transplantable cell-encapsulation device using a semipermeable ethylene-vinyl alcohol copolymer membrane in a mouse diabetic model | |
EP3373993B1 (en) | Si-hpmc-encapsulated insulin-producing cells for the treatment of type 1 diabetes | |
US20210196646A1 (en) | Improved formulations for pancreatic islet encapsulation | |
CN106421925A (zh) | 基于糖胺聚糖仿生细胞外基质水凝胶作为胰岛培养支架的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190201 |
|
RJ01 | Rejection of invention patent application after publication |